Holen Sie sich die Stockscreener-App
0.4371
4.98%
-0.0229
Handel nachbörslich:
.45
0.0129
+2.95%
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Gossamer Bio options imply 46.1% move in share price post-earnings - Yahoo Finance
Gossamer Bio Inc Stock (ISIN: US38198T1034) Surges on Clinical Momentum and Analyst Optimism - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Shareholders to Reach Out - ACCESS Newswire
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire
GOSS Stock Quote Price and Forecast - CNN
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - ChartMill
GOSS Gossamer Bio NASDAQ $0.56 10 Mar 2026: Pre-market ahead of Mar 12 earnings - Meyka
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
Can Gossamer Bio Inc withstand a market correction2026 Volume Leaders & Verified Swing Trading Watchlists - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Gossamer Bio Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect - ACCESS Newswire
GOSS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts remain bullish on Gossamer Bio (GOSS) citing undervaluation - MSN
683 Capital Management, LLC Increases Stake in Gossamer Bio Inc - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
HC Wainwright Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $5.00 - MarketBeat
GOSS: HC Wainwright & Co. Lowers Price Target Despite Maintainin - GuruFocus
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 - Sahm
Oppenheimer Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $3.00 - MarketBeat
Oppenheimer Maintains Outperform Rating, Lowers PT on Gossamer B - GuruFocus
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline - sharewise.com
GOSS: Announces Topline Results for Phase 3 PROSERA Trial — LEVI & KORSINSKY, LLP - The Malaysian Reserve
Gossamer Bio to Report Q4 2025 Earnings on Thursday - National Today
Gossamer Bio (GOSS) to Release Earnings on Thursday - MarketBeat
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of "Hold" by Brokerages - MarketBeat
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Stockholders to Connect - ACCESS Newswire
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm - MEXC
2026-03-01 | Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
Should You Buy Gossamer Bio Inc (GOSS) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-02-27 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Gossamer Bio, Inc. (GOSS) Stock Analysis: Exploring the 1,395.85% Potential Upside for Investors - DirectorsTalk Interviews
Gossamer Bio (NASDAQ:GOSS) Downgraded to Hold Rating by The Goldman Sachs Group - MarketBeat
Guggenheim Sticks to Their Hold Rating for Gossamer Bio (GOSS) - The Globe and Mail
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Finviz
Quarterly Trades: Should I set a stop loss on Gossamer Bio IncJuly 2025 Trends & Technical Pattern Based Signals - baoquankhu1.vn
Gossamer, Grail down by more than half after late-stage misses - biocentury.com
Barclays downgrades Gossamer Bio (GOSS) - MSN
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Re - GuruFocus
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):